Cyclophosphamide (generic), Cytoxan Newswire (Page 6)

Cyclophosphamide (generic), Cytoxan Newswire (Page 6)

Comprehensive Real-Time News Feed for Cyclophosphamide (generic), Cytoxan. (Page 6)

Results 101 - 120 of 384 in Cyclophosphamide (generic), Cytoxan

  1. Myeloma UK opens MUK eight a clinical trial of the oral proteasome inhibitor ixazomibRead the original story w/Photo

    Jan 14, 2016 | Medical News Today

    Myeloma UK announces that MUK eight, a Phase II trial of the oral proteasome inhibitor, ixazomib, is now open for recruitment. MUK eight is a randomised Phase II trial comparing the novel oral proteasome inhibitor ixazomib in combination with cyclophosphamide and dexamethasone, against a combination of cyclophosphamide and dexamethasone in relapsed and/or refractory myeloma patients.

    Comment?

  2. Insulin-like growth factor-I-dependent growth and in vitro...Read the original story

    Jan 12, 2016 | CiteULike

    Insulin-like growth factor-I-dependent growth and in vitro chemosensitivity of Ewing's sarcoma and peripheral primitive neuroectodermal tumour cell lines. To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.

    Comment?

  3. Membranoproliferative glomerulonephritis recurrence after kidney...Read the original story

    Jan 10, 2016 | BioMed Central

    Membranoproliferative glomerulonephritis is an uncommon glomerular disorder that may lead to end stage renal disease . With new understanding of the disease pathogenesis, the classical classification as MPGN types I, II, III has changed.

    Comment?

  4. Introduction of Combined CHOP Plus Rituximab Therapy Dramatically...Read the original story

    Jan 11, 2016 | CiteULike

    Journal of Clinical Oncology , Vol. 23, No. 22. , pp. 5027-5033, doi:10.1200/jco.2005.09.137 To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.

    Comment?

  5. The Role of Consolidative Radiotherapy after a Complete Response to...Read the original story

    Jan 11, 2016 | CiteULike

    The Role of Consolidative Radiotherapy after a Complete Response to Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma in the Rituximab Era: Results from a Systematic Review with a Meta-Analysis. The current standard therapy for patients with diffuse large B-cell lymphoma is rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone .

    Comment?

  6. Differentiation of sarcoidosis-lymphoma syndrome lesions: a case...Read the original story

    Jan 7, 2016 | BioMed Central

    Sarcoidosis-lymphoma syndrome is a rare disease in which both entities coexist. We aimed to study the role of 18F-fluorodeoxyglucose and L-[3-18F] AZA -methyltyrosine positron emission tomography /computed tomography in differentiating between these two lesions.

    Comment?

  7. [Research Articles] Early memory phenotypes drive T cell...Read the original story

    Jan 6, 2016 | Science

    Adoptive cell therapies with engineered T cells have shown promising results in patients whose cancer is recalcitrant to other therapies. However, chemotherapy can inhibit both the expansion and function of T cells, limiting the success of this approach.

    Comment?

  8. Minimal residual disease assessed by multi-parameter flow cytometry...Read the original story

    Jan 6, 2016 | CiteULike

    The prognostic value of minimal residual disease assessed by multi-parameter flow cytometry was investigated among 340 adult patients with B-cell acute lymphoblastic leukaemia treated between 2004 and 2014 using regimens including the hyperCVAD backbone. Among them, 323 achieved complete remission and were included in this study.

    Comment?

  9. ChemoCentryx, Inc. Announces Positive Results In Phase II...Read the original story

    Jan 5, 2016 | BioSpace

    ChemoCentryx, Inc. Announces Positive Results In Phase II ANCA-Associated Vasculitis CLEAR Trial Of Orally Administered Complement 5a Receptor Inhibitor CCX168 -- Primary endpoint achieved: CCX168 demonstrates numerical superiority and achieves statistical significance in test for non-inferiority in BVAS response relative to standard of care -- -- Treatment with CCX168 successful in eliminating high-dose oral corticosteroids from current standard-of-care regimen without compromising efficacy -- -- CCX168 treatment resulted in rapid and pronounced improvements in BVAS, albuminuria, and other indicators of renal disease, as well as quality of life assessments -- -- CCX168 appears safe and well tolerated -- -- Company plans to advance CCX168 into Phase III development in AAV in 2016 -- -- Conference call and webcast with topline data presentation today at 8:30 a.m. Eastern Time -- MOUNTAIN ... (more)

    Comment?

  10. ChemoCentryx Announces Positive Results in Phase II Anca-Associated...Read the original story w/Photo

    Jan 6, 2016 | GlobeNewswire

    ChemoCentryx Announces Positive Results in Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 -- Primary endpoint achieved: CCX168 demonstrates numerical superiority and achieves statistical significance in test for non-inferiority in BVAS response relative to standard of care -- -- CCX168 treatment resulted in rapid and pronounced improvements in BVAS, albuminuria, and other indicators of renal disease, as well as quality of life assessments -- MOUNTAIN VIEW, Calif., Jan. 06, 2016 -- ChemoCentryx, Inc., , a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, today announced positive top-line data from its' Phase II CLEAR trial with CCX168 in patients with anti-neutrophil cytoplasmic antibody -associated vasculitis, or AAV.

    Comment?

  11. Low immunoglobulin levels increase the risk of severe...Read the original story

    Jan 5, 2016 | BioMed Central

    Randomized controlled trials and retrospective studies in ANCA-associated vasculitis concurred that rituximab is effective to induce and maintain remission. Infections and hypogammaglobulinemia during RTX were usually infrequent and uncomplicated.

    Comment?

  12. All-trans retinoic acid synergizes with topotecan to suppress AML...Read the original story

    Jan 4, 2016 | BioMed Central

    Chemotherapy is the only therapy option for the majority of AML patients, however, there are several limitations for this treatment. Our aim was to find a new chemotherapy strategy that is more effective and less toxic.

    Comment?

  13. Comparable Outcomes for Hematologic Malignancies after...Read the original story

    Jan 4, 2016 | CiteULike

    The implementation of high-dose posttransplantation cyclophosphamide has made HLA-haploidentical blood or marrow transplantation a cost effective and safe alternative donor transplantation technique, resulting in its increasing utilization over the last decade. We review the available retrospective comparisons of haplo BMT with PTCy and HLA-matched BMT in adults with hematologic malignancies.

    Comment?

  14. Phase II study of a high-dose ifosfamide-based chemotherapy regimen...Read the original story

    Jan 1, 2016 | CiteULike

    Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival.

    Comment?

  15. Incidence and characteristics of invasive fungal diseases in...Read the original story

    Dec 28, 2015 | BioMed Central

    This retrospective cohort study at the Medical University of Vienna aspired to assess the incidence, characteristics and the outcome of IFDs as well as the associated risk factors in a setting where only 43 % of patients were given systemic antifungal prophylaxis during aplasia. IFDs were classified as probable or proven according to the EORTC/MSG consensus group.

    Comment?

  16. Analysts' Recent Ratings Updates for Cellectis SARead the original story w/Photo

    Dec 22, 2015 | AmericanBankingNews.com

    According to Zacks, "Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells.

    Comment?

  17. Antineoplastic agent obscures diagnosis of fungal meningitisRead the original story w/Photo

    Dec 17, 2015 | PhysOrg Weblog

    A case of cryptococcal meningitis with false-negative cerebrospinal fluid culture results following receipt of capecitabine has been described in a case report published in the December issue of the Journal of Clinical Pharmacy and Therapeutics . William R. Judd, Pharm.D., from the Saint Joseph Hospital in Lexington, Ky., and colleagues document the case of a 78-year-old man with a history of chronic lymphocytic leukemia who presented to the emergency department with increasing bilateral extremity weakness, dizziness, and gait disturbances.

    Comment?

  18. HLA-haploidentical donor lymphocyte infusions for patients with...Read the original story

    Dec 16, 2015 | CiteULike

    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation , Vol. 20, No.

    Comment?

  19. Stem cell transplantation does not provide significant improvement for Crohn's diseaseRead the original story w/Photo

    Dec 15, 2015 | PhysOrg Weblog

    Among adults with difficult to treat Crohn disease not amenable to surgery, hematopoietic stem cell transplantation, compared with conventional therapy, did not result in significant improvement in sustained disease remission at l year and was associated with significant toxicity, according to a study in the December 15 issue of JAMA . Crohn disease is a chronic relapsing inflammatory condition of the gastrointestinal tract that can result in life-long ill health, impaired quality of life, and reduced life expectancy.

    Comment?

  20. 10-Year Follow-Up Analysis Of BCIRG-006 Study ByRead the original story

    Dec 10, 2015 | BioSpace

    The analysis also showed that this efficacy benefit is very similar in the anthracycline and non-anthracycline based, trastuzumab-containing regimens; however, the non-anthracycline regimen was associated with an important improvement in long-term cardiac safety . The BCIRG-006 trial evaluated three regimens after initial surgery: 4 cycles of doxorubicin and cyclophosphamide followed by 4 cycles of docetaxel versus 4 cycles of doxorubicin and cyclophosphamide followed by 4 cycles of docetaxel and one year of Herceptin versus a non-anthracycline regimen of 6 cycles of docetaxel plus carboplatin and one year of trastuzumab .

    Comment?